A guide to GERD, &lt;i&gt;H pylori&lt;/i&gt; infection, and Barrett esophagus

,; ,; ,

Applied Evidence

A guide to GERD, H pylori infection, and Barrett esophagus

J Fam Pract. 2022 June;71(5):E1-E7

PDF Download

References

1. Wang C, Yuan Y, Hunt RH. Helicobacter pylori infection and Barrett’s esophagus: a systematic review and meta-analysis. Am J Gastroenterol. 2009;104:492-500. doi: 10.1038/ajg.2008.37

2. Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal reflux disease: a review. JAMA. 2020;324:2536-2547. doi: 10.1001/jama.2020.21360

3. Scida S, Russo M, Miraglia C, et al. Relationship between Helicobacter pylori infection and GERD. Acta Biomed. 2018;89:40-43. doi: 10.23750/abm.v89i8-S.7918

4. Vakil N, Van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900-1920. doi: 10.1111/j.1572-0241.2006.00630.x

5. Mikami DJ, Murayama KM. Physiology and pathogenesis of gastroesophageal reflux disease. Surg Clin North Am. 2015;95:515-525. doi: 10.1016/j.suc.2015.02.006

6. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308-328. doi: 10.1038/ajg.2012.444

7. Sidhwa F, Moore A, Alligood E, et al. Diagnosis and treatment of the extraesophageal manifestations of gastroesophageal reflux disease. Ann Surg. 2017;265:63-67. doi: 10.1097/SLA.0000000000001907

8. Eusebi LH, Ratnakumaran R, Yuan Y, et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67:430-440. doi: 10.1136/gutjnl-2016-313589

9. Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112:212-239. doi: 10.1038/ajg.2016.563

10. Eusebi LH, Cirota GG, Zagari RM, et al. Global prevalence of Barrett’s oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis. Gut. 2021;70:456-463. doi: 10.1136/gutjnl-2020-321365

11. Shaheen NJ, Falk GW, Iyer PG, et al; American College of Gastroenterology. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30-50. doi: 10.1038/ajg.2015.322

12. Savarino E, Bredenoord AJ, Fox M, et al; International Working Group for Disorders of Gastrointestinal Motility and Function. Expert consensus document: advances in the physiological assessment and diagnosis of GERD. Nat Rev Gastroenterol Hepatol. 2017;14:665-676. doi: 10.1038/nrgastro.2017.130

13. Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med. 2008;359:1700-1707. doi: 10.1056/NEJMcp0804684

14. Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152:706-715. doi: 10.1053/j.gastro.2017.01.031

15. Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66:516-554. doi: 10.1097/MPG.0000000000001889

16. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1383-1391. doi: 10.1053/j.gastro.2008.08.045

17. Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018;16:800-808. doi: 10.1016/j.cgh.2017.09.033

18. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157:682-691. doi: 10.1053/j.gastro.2019.05.056

19. Katzka DA, Kahrilas PJ. Advances in the diagnosis and management of gastroesophageal reflux disease. BMJ. 2020;371:m3786. doi: 10.1136/bmj.m3786

20. Ali RA, Egan LJ. Gastroesophageal reflux disease in pregnancy. Best Pract Res Clin Gastroenterol. 2007;21:793-806. doi: 10.1016/j.bpg.2007.05.006

21. Body C, Christie JA. Gastrointestinal diseases in pregnancy: nausea, vomiting, hyperemesis gravidarum, gastroesophageal reflux disease, constipation, and diarrhea. Gastroenterol Clin North Am. 2016;45:267-283. doi: 10.1016/j.gtc.2016.02.005

22. Lightdale JR, Gremse DA, et al. Gastroesophageal reflux: management guidance for the pediatrician. Pediatrics. 2013;131;e1684-e1695. doi: 10.1542/peds.2013-0421

23. Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153:420-429. doi: 10.1053/j.gastro.2017.04.022

24. Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47:868-876. doi: 10.1111/apt.14561

25. Choi IJ, Kim CG, Lee JY, et al. Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med. 2020;382:427-436. doi: 10.1056/NEJMoa1909666

26. Gisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis. Am J Gastroenterol. 2006;101:848-863. doi: 10.1111/j.1572-0241.2006.00528.x

27. Best LM, Takwoingi Y, Siddique S, et al. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev. 2018;3:CD012080. doi: 10.1002/14651858.CD012080.pub2

28. Howden CW, Graham DY. Recent developments pertaining to H. pylori infection. Am J Gastroenterol. 2021;116:1-3. doi: 10.14309/ajg.0000000000001031

29. Shah SC, Iyer PG, Moss SF. AGA Clinical practice update on the management of refractory Helicobacter pylori infection: expert review. Gastroenterology. 2021;160:1831-1841. doi: 10.1053/j.gastro.2020.11.059

30. Yang-Ou YB, Hu Y, Zhu Y, et al. The effect of antioxidants on Helicobacter pylori eradication: a systematic review with meta-analysis. Helicobacter. 2018;23:e12535. doi: 10.1111/hel.12535

31. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140:1084-1091. doi: 10.1053/j.gastro.2011.01.030

32. Codipilly DC, Chandar AK, Singh S, et al. The effect of endoscopic surveillance in patients with Barrett’s esophagus: a systematic review and meta-analysis. Gastroenterology. 2018;154:2068-2086. doi: 10.1053/j.gastro.2018.02.022

33. Singh S, Garg SK, Singh PP, et al. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut. 2014;63:1229-1237. doi: 10.1136/gutjnl-2013-305997

34. Jankowski JAZ, de Caestecker J, Love SB, et al. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial. Lancet. 2018;392:400-408. doi: 10.1016/S0140-6736(18)31388-6

35. Hu Q, Sun TT, Hong J, et al. Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: a systematic review and meta-analysis. PLoS One. 2017;12:e0169691. doi: 10.1371/journal.pone.0169691

Additionally, adequate acid suppression is directly related to successful eradication. Thus, the likelihood of treatment success can be improved by using higher doses of PPIs and avoiding ones that are more likely to be metabolized quickly in some patients (lansoprazole, omeprazole). Patient adherence to the treatment regimen is an important determinant of effectiveness.^9,29 Adding vitamin C 400 to 1000 mg/d, vitamin E 100 to 400 mg/d, and probiotics may improve the effectiveness of treatment.^9,30

Duration of treatment is directly related to treatment effectiveness. Whenever possible, opt for 14 days of treatment instead of just 7.⁹

Test of cure. Patients treated for H pylori should be re-tested no sooner than 4 weeks after completion of therapy. Urea breath testing, stool antigen testing, and endoscopic biopsies (if endoscopy is indicated for some other reason) can all be used post treatment for test of cure.⁹

Barrett esophagus

Chronic reflux can lead to BE, in which metaplastic columnar epithelium replaces the normal squamous epithelium lining the distal esophagus. BE is linked to dysplasia and esophageal adenocarcinoma (EAC).¹¹ Endoscopic examination with biopsy is used to diagnosis BE. The global prevalence of histology-confirmed BE in people with GERD symptoms is 7.2%.¹⁰ Similar to GERD and H pylori infections, the prevalence of BE varies significantly with geographic location (14% in North America; 3% in the Middle East).¹⁰ BE is twice as likely to occur in men as in women, and it is rare in children.¹⁰

Whom to screen

The American College of Gastroenterology recommends consideration of screening with upper endoscopy for men with chronic GERD (> 5 years) or frequent GERD symptoms (once weekly or more often), plus 2 or more of the following risk factors: age > 50 years, Caucasian race, central obesity, smoking (current or past), or a family history of BE or EAC (TABLE 1^2,9-11). Screening for BE in women is not routinely recommended but can be considered in individuals with several of the risk factors just described.

Continue to: Not everyone with BE...